Peter Gajdos is a managing director and a portfolio manager in Presidio, San Francisco-based VC fund. Presidio is a multi-sector, deep technology-focused VC fund investing in IT, life sciences, energy and materials. In the last five years, Presidio Partners returned over US$750m in cash to Limited Partners. The fund had eight initial public offerings (“IPOs”) with Peter’s direct involvement in five of them. Peter is an experienced board member, having sat on boards of several companies such as: (i) CNano Technology (former – sold to Chinese strategic); (ii) Arcadia Biosciences (Former board member – IPO: NASDAQ: RKDA); (iii) Reel Solar (Former board member – acquired by a Chinese strategic company); (iv) Corsair Pharma; (v) ESS Inc. (Observer) (vi) Wildcat Discovery Technologies (Observer); (vii) NeuroRecovery Technologies (Observer); (viii) Auspex Pharmaceuticals (Former observer – IPO: NASDAQ: ASPX and later acquired by Teva for EUR3.3bn); (ix) Ardelyx (Former observer – IPO: NASDAQ: ARDX); (x) Neos Therapeutics (Former observer – IPO: NASDAQ: NEOS); (xi) Exela Pharma Sciences (Observer); (xii) SurgiQuest (Observer – acquired by ConMed for EUR247m) and (xiii) Menlo Therapeutics (Former observer – IPO: NASDAQ: MNLO). Previously, Peter worked with SilverLake Kraftwerk and with Warburg Pincus focusing on energy and technology investments. Peter also worked as an Associate at Virgin Green Fund, a private equity fund that provides growth and scale-up capital to companies operating in the renewables and efficiency sectors optimising natural resources in North America, Europe and Israel. Prior to working at Virgin Green Fund, Peter worked in New York as an investment banker at J.P. Morgan. Peter holds an MBA from the Wharton School, University of Pennsylvania.